Rare disease star drug is withdrawn from the market in the United States due to death cases, Anjin responds to China: It has not been commercialized in China, and no patients have received treatment.

Recently, due to liver damage-related deaths, the rare disease treatment drug Afinitor capsule from the American company Novartis has been proposed for withdrawal from the market by US regulators, even though the drug had previously been approved in the Chinese market. On May 22nd, Novartis China stated that in China, Afinitor capsule had been approved by the China National Medical Products Administration in November 2024, but has not yet been commercially launched, and as of now no patients in China have received treatment with Afinitor.